

# Darcy A Krueger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5865497/publications.pdf>

Version: 2024-02-01

95  
papers

6,699  
citations

136885

32  
h-index

62565

80  
g-index

98  
all docs

98  
docs citations

98  
times ranked

5635  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	1.0	1,185
2	Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. <i>New England Journal of Medicine</i> , 2010, 363, 1801-1811.	13.9	906
3	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	1.0	693
4	Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. <i>Annals of Neurology</i> , 2013, 74, 679-687.	2.8	332
5	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	1.0	230
6	Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. <i>PLoS Genetics</i> , 2015, 11, e1005637.	1.5	209
7	Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. <i>Neurology</i> , 2013, 80, 574-580.	1.5	180
8	Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease. <i>PLoS ONE</i> , 2011, 6, e23379.	1.1	177
9	Diagnostic methods and treatment options for focal cortical dysplasia. <i>Epilepsia</i> , 2015, 56, 1669-1686.	2.6	167
10	The genomic landscape of tuberous sclerosis complex. <i>Nature Communications</i> , 2017, 8, 15816.	5.8	154
11	Influence of seizures on early development in tuberous sclerosis complex. <i>Epilepsy and Behavior</i> , 2017, 70, 245-252.	0.9	132
12	Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. <i>Annals of Neurology</i> , 2015, 78, 929-938.	2.8	130
13	Long-term treatment of epilepsy with everolimus in tuberous sclerosis. <i>Neurology</i> , 2016, 87, 2408-2415.	1.5	130
14	Lymphangiomyomatosis Screening in Women With Tuberous Sclerosis. <i>Chest</i> , 2013, 144, 578-585.	0.4	129
15	Cardiovascular Manifestations of Tuberous Sclerosis Complex and Summary of the Revised Diagnostic Criteria and Surveillance and Management Recommendations From the International Tuberous Sclerosis Consensus Group. <i>Journal of the American Heart Association</i> , 2014, 3, e001493.	1.6	128
16	Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. <i>Neuro-Oncology</i> , 2015, 17, 1550-1559.	0.6	123
17	Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. <i>Pediatric Neurology</i> , 2016, 54, 29-34.	1.0	93
18	Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 877-887.	1.7	92

#	ARTICLE	IF	CITATIONS
19	Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. <i>Pediatrics</i> , 2017, 140, .	1.0	90
20	Analysis of head impact exposure and brain microstructure response in a season-long application of a jugular vein compression collar: a prospective, neuroimaging investigation in American football. <i>British Journal of Sports Medicine</i> , 2016, 50, 1276-1285.	3.1	68
21	Everolimus alters white matter diffusion in tuberous sclerosis complex. <i>Neurology</i> , 2012, 78, 526-531.	1.5	67
22	The Effects of External Jugular Compression Applied during Head Impact Exposure on Longitudinal Changes in Brain Neuroanatomical and Neurophysiological Biomarkers: A Preliminary Investigation. <i>Frontiers in Neurology</i> , 2016, 7, 74.	1.1	58
23	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 1066-1073.	0.7	54
24	Current Management of Tuberous Sclerosis Complex. <i>Paediatric Drugs</i> , 2008, 10, 299-313.	1.3	49
25	Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. <i>Current Medical Research and Opinion</i> , 2012, 28, 657-663.	0.9	49
26	Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism. <i>Neurotherapeutics</i> , 2015, 12, 572-583.	2.1	47
27	Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complex. <i>Clinical Neurophysiology</i> , 2018, 129, 1458-1466.	0.7	46
28	Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study. <i>Epilepsia</i> , 2019, 60, 2428-2436.	2.6	45
29	Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2011, 20, 266-270.	0.9	44
30	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. <i>Pediatric Neurology</i> , 2016, 60, 1-12.	1.0	43
31	Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 105, 59-61.	1.0	38
32	Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. <i>Epilepsia</i> , 2019, 60, 1721-1732.	2.6	37
33	Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study. <i>Pediatric Neurology</i> , 2020, 106, 10-16.	1.0	37
34	Central nervous system manifestations of tuberous sclerosis complex. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2018, 178, 291-298.	0.7	36
35	Reproducibility of Structural and Diffusion Tensor Imaging in the TACERN Multi-Center Study. <i>Frontiers in Integrative Neuroscience</i> , 2019, 13, 24.	1.0	32
36	Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorder. <i>Journal of Neurodevelopmental Disorders</i> , 2019, 11, 36.	1.5	32

#	ARTICLE	IF	CITATIONS
37	Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex. Current Treatment Options in Neurology, 2013, 15, 618-633.	0.7	29
38	Utility of the Autism Observation Scale for Infants in Early Identification of Autism in Tuberous Sclerosis Complex. Pediatric Neurology, 2017, 75, 80-86.	1.0	28
39	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Research, 2018, 148, 1-7.	0.8	25
40	Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network. Annals of Neurology, 2021, 89, 726-739.	2.8	24
41	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. Pediatric Neurology, 2020, 109, 39-46.	1.0	23
42	Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex. PLoS ONE, 2020, 15, e0232376.	1.1	23
43	Everolimus for Tumor Recurrence After Surgical Resection for Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex. Journal of Child Neurology, 2013, 28, 602-607.	0.7	22
44	Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. Journal of Pediatrics, 2017, 187, 318-322.e2.	0.9	22
45	Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. Pediatric Neurology, 2019, 96, 58-63.	1.0	21
46	Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. Pediatric Neurology, 2019, 90, 24-30.	1.0	21
47	Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex. Annals of Clinical Psychiatry, 2011, 23, 263-9.	0.6	21
48	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2015, 21, 1558-1565.	3.2	20
49	Vigabatrin for Childhood Partial-Onset Epilepsies. Pediatric Neurology, 2012, 46, 83-88.	1.0	19
50	Epilepsy treatment patterns among patients with tuberous sclerosis complex. Journal of the Neurological Sciences, 2018, 391, 104-108.	0.3	19
51	Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. Pediatric Neurology, 2017, 72, 81-85.	1.0	17
52	Prenatal Sirolimus Treatment for Rhabdomyomas in Tuberous Sclerosis. Pediatric Neurology, 2021, 125, 26-31.	1.0	16
53	Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study. Current Medical Research and Opinion, 2012, 28, 651-656.	0.9	15
54	Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells. Molecular Cancer Research, 2017, 15, 1318-1330.	1.5	14

#	ARTICLE	IF	CITATIONS
55	Language predictors of autism spectrum disorder in young children with tuberous sclerosis complex. <i>Epilepsy and Behavior</i> , 2020, 103, 106844.	0.9	14
56	Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex. <i>Journal of Neuroscience Nursing</i> , 2013, 45, 226-242.	0.7	13
57	Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study. <i>Annals of Neurology</i> , 2021, 90, 874-886.	2.8	13
58	Functional Analysis of the Mouse ICER (Inducible cAMP Early Repressor) Promoter: Evidence for a Protein That Blocks Calcium Responsiveness of the CAREs (cAMP Autoregulatory Elements). <i>Molecular Endocrinology</i> , 1999, 13, 1207-1217.	3.7	11
59	â€œBenignâ€™ ovarian teratoma and N-methyl-D-aspartate receptor (NMDAR) encephalitis in a child. <i>Pediatric Radiology</i> , 2012, 42, 120-123.	1.1	11
60	Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis. <i>PLoS ONE</i> , 2013, 8, e56199.	1.1	11
61	The Connectivity Fingerprint of the Fusiform Gyrus Captures the Risk of Developing Autism in Infants with Tuberous Sclerosis Complex. <i>Cerebral Cortex</i> , 2020, 30, 2199-2214.	1.6	11
62	Lymphangioliomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2021, 18, 815-819.	1.5	10
63	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. <i>PLoS ONE</i> , 2017, 12, e0186235.	1.1	10
64	Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 447.	1.2	10
65	Cerebellar volume as an imaging marker of development in infants with tuberous sclerosis complex. <i>Neurology</i> , 2018, 90, e1493-e1500.	1.5	9
66	Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.. <i>American Psychologist</i> , 2019, 74, 356-367.	3.8	9
67	Lymphangioliomyomatosis Mortality in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2019, 16, 509-512.	1.5	9
68	Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 113, 46-50.	1.0	9
69	The research landscape of tuberous sclerosis complexâ€™ associated neuropsychiatric disorders (TAND)â€™ a comprehensive scoping review. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, 13.	1.5	9
70	Involvement of Thyrotroph Embryonic Factor in Calcium-mediated Regulation of Gene Expression. <i>Journal of Biological Chemistry</i> , 2000, 275, 14524-14531.	1.6	7
71	Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas. <i>Urology</i> , 2017, 104, 110-114.	0.5	7
72	Thoracoabdominal imaging of tuberous sclerosis. <i>Pediatric Radiology</i> , 2018, 48, 1307-1323.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. <i>Frontiers in Neurology</i> , 2021, 12, 627672.	1.1	7
74	Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study. <i>Journal of Medical Economics</i> , 2015, 18, 349-356.	1.0	6
75	Resting-State fMRI Networks in Children with Tuberous Sclerosis Complex. <i>Journal of Neuroimaging</i> , 2019, 29, 750-759.	1.0	6
76	Learning to Detect Brain Lesions from Noisy Annotations. , 2020, 2020, 1910-1914.		5
77	Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2021, 123, 1-9.	1.0	5
78	Empowering Families Through Technology: A Mobile-Health Project to Reduce the TAND Identification and Treatment Gap (TANDem). <i>Frontiers in Psychiatry</i> , 2022, 13, 834628.	1.3	5
79	Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 60.	1.5	5
80	Non-alcoholic Wernicke Encephalopathy. <i>Pediatric Neurology</i> , 2016, 56, 94-95.	1.0	4
81	Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma. <i>Current Medical Research and Opinion</i> , 2019, 35, 1103-1110.	0.9	4
82	Targeting mTOR complex 1 to treat neurological and psychiatric manifestations of tuberous sclerosis complex. <i>Future Neurology</i> , 2011, 6, 261-271.	0.9	3
83	Automated Detection of High Frequency Oscillations in Human Scalp Electroencephalogram. , 2018, 2018, 3116-3119.		3
84	Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors. <i>Pediatric Neurology</i> , 2021, 120, 7-10.	1.0	3
85	Functional Analysis of the Mouse ICER (Inducible cAMP Early Repressor) Promoter: Evidence for a Protein That Blocks Calcium Responsiveness of the CAREs (cAMP Autoregulatory Elements). <i>Molecular Endocrinology</i> , 1999, 13, 1207-1217.	3.7	3
86	EEG Spectral Features in Sleep of Autism Spectrum Disorders in Children with Tuberous Sclerosis Complex. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 916-923.	1.7	2
87	Prevalence of thoracoabdominal imaging findings in tuberous sclerosis complex. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 124.	1.2	2
88	Limited utility of structural MRI to identify the epileptogenic zone in young children with tuberous sclerosis. <i>Journal of Neuroimaging</i> , 0, , .	1.0	2
89	mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. <i>Radiology Imaging Cancer</i> , 2020, 2, e190091.	0.7	1
90	Reply. <i>Annals of Neurology</i> , 2014, 75, 164-165.	2.8	0

#	ARTICLE	IF	CITATIONS
91	Oral Manifestations and Quality of Life in Children with Tuberous Sclerosis Complex: A Descriptive Study. <i>Pediatric Dentistry (discontinued)</i> , 2021, 43, 140-144.	0.4	0
92	Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex. , 2020, 15, e0232376.		0
93	Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex. , 2020, 15, e0232376.		0
94	Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex. , 2020, 15, e0232376.		0
95	Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex. , 2020, 15, e0232376.		0